BEGIN:VCALENDAR
PRODID:-//github.com/rianjs/ical.net//NONSGML ical.net 4.0//EN
VERSION:2.0
BEGIN:VEVENT
DESCRIPTION:With the number of new clinical ADC targets reaching an all-ti
 me high\, the 3rd ADC Target Selection Summit returns as the only industr
 y-specific meeting spotlighting the latest developments in the field that
  will continue progressing first- and best-in-class ADCs through the clin
 ic.\n\nProviding a greater focus on identifying and validating novel targ
 ets\, re-examining what makes a good target\, and analyzing how novel lin
 ker-payload technologies are changing the target selection paradigm\; thi
 s is your unique opportunity to delve into the use of proteomics to ensur
 e you get the first step of drug development right.\n\nWith 100+ ADC enth
 usiasts set to be in the room including Iksuda Therapeutics\, Merck and C
 o\, Angiex\, Ziel Bio\, and Seagen\; this is your chance to connect with 
 peers working exclusively in biology\, discovery\, translational\, target
  identification and validation.\n\nFacilitating conversations on both the
  scientific and strategic elements of target selection for antibody-drug 
 conjugates\, this meeting will address all important discussions to infor
 m your target selection and balance risk in your ADC pipeline for 2024 an
 d beyond.\n\nURLs:Tickets:&nbsp\;https://go.evvnt.com/1868494-2?pid=185Br
 ochure:&nbsp\;https://go.evvnt.com/1868494-3?pid=185\n\nPrices:Drug Devel
 oper Pricing - Conference + Pre Conference Workshop Day: USD 4297.00\,Dru
 g Developer Pricing - Conference Only: USD 2999.00\,Academic Pricing - Co
 nference + Pre Conference Workshop Day: USD 3697.00\,Academic Pricing - C
 onference Only: USD 2599.00\,Solution Provider Pricing - Conference + Pre
  Conference Workshop Day: USD 5297.00\,Solution Provider Pricing - Confer
 ence Only: USD 3799.00\n\nSpeakers:&nbsp\;Alexander Scholz\, Senior Direc
 tor\, Atreca\, Bill Mallet\, Senior Director\, Target Validation\, Bolt B
 iotherapeutics\, Carl Barrett\, Vice-President\, Translational Sciences\,
  Former AstraZeneca\, Daniel Calarese\, Director of Innovation and Strate
 gy\, Sutro Biopharma\, Dowdy Jackson\, Executive Director\, Research\, In
 novent Biologics\, Elaine Hurt. Executive Director\, Tumor Targeted Deliv
 ery\, AstraZeneca\, Hanspeter Gerber\, Chief Scientific Officer and Co-Fo
 under\, Codeable Therapeutics\, Jamie Rich\, Director\, Technology\, Zyme
 works\, Jay Mettetal\, Senior Director - Oncology Bioscience\, AstraZenec
 a\, Kimberly Kelly\, Scientific Founder\, President and Chief Operating O
 fficer\, Ziel Bio\, Lesley Jenkinson\, Principal Scientist\, Cancer Resea
 rch Horizons\, Manoj Charati\, Principal Scientist\, Merck and Co.\, Mart
 ha Neagu\, Medical Director\, AbbVie\, Mary Hu\, Chief Executive Officer\
 , Shanghai Miracogen\, Natalie Grinshtein\, Director - Cancer Target Disc
 overy. Seagen\, Randy Milby\, Chief Executive Officer and Chairman\, Hill
 stream BioPharma\, Robert Lutz\, Chief Scientific Officer\, Iksuda Therap
 eutics\, Shou-Ching\, Jaminet Founder\, Angiex\, Stefan Ries\, Chief Scie
 ntific Officer\, R and D\, DISCO Therapeutics\, Steve Ludbrook\, Director
  of Molecular Pharmacology\, Bicycle Therapeutics\, Zhinan Xia\, Chief Sc
 ientific Officer\, DynamiCure Biotechnology\n\nCategory:&nbsp\;Conference
 s | Science\, Health and Medicine | Pharmaceuticals\n\nDate and Time:&nbs
 p\;5th December 2023 at 9:00 am to 7th December 2023 at 5:00 pm\n
DTEND:20231207T170000
DTSTAMP:20260512T234700Z
DTSTART:20231205T090000
LOCATION:Hilton Boston Logan Airport\, One\, Hotel Drive\, Boston\, Massac
 husetts\, 02128\,
SEQUENCE:0
SUMMARY:With the number of new clinical ADC targets reaching an all-time h
 igh\, the 3rd ADC Target Selection Summit returns as the only industry-sp
 ecific me...
UID:0fd08aad-22e1-4d99-8e6e-baef12502bed
END:VEVENT
END:VCALENDAR